---
title: 'Treatment of adult ALL patients with third-generation CD19-directed CAR T
  cells: results of a pivotal trial'
date: '2023-07-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37481608/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230723180823&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: In conclusion, third-generation CARTs were associated with
  promising clinical efficacy and remarkably low procedure-specific toxicity, thereby
  opening new therapeutic perspectives for patients with r/r ALL. Trial registration
  This trial was registered at ...'
disable_comments: true
---
CONCLUSION: In conclusion, third-generation CARTs were associated with promising clinical efficacy and remarkably low procedure-specific toxicity, thereby opening new therapeutic perspectives for patients with r/r ALL. Trial registration This trial was registered at ...